Effective Therapy of Tocilizumab on Systemic Juvenile Idiopathic Arthritis Associated Refractory Macrophage Activation Syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Modern rheumatology"
DOI: 10.1093/mr/roab119
Abstract: OBJECTIVES To evaluate the safety and efficacy of tocilizumab (TCZ) on refractory macrophage activation syndrome (rMAS) associated with systemic juvenile idiopathic arthritis (sJIA-rMAS). METHODS We retrospectively reviewed the charts of 14 patients diagnosed with sJIA-rMAS,… read more here.
Keywords: arthritis; tcz; macrophage activation; refractory macrophage ... See more keywords